NASDAQ:BVXV

BiondVax Pharmaceuticals News Headlines

$3.09
+0.07 (+2.32 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.00
Now: $3.09
$3.18
50-Day Range
$3.02
MA: $3.91
$4.41
52-Week Range
$2.35
Now: $3.09
$62.00
Volume101,100 shs
Average Volume928,060 shs
Market Capitalization$35.08 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41

Headlines

BiondVax Pharmaceuticals (NASDAQ BVXV) News Headlines Today

SourceHeadline
BiondVax Pharmaceuticals (NASDAQ:BVXV) Shares Pass Below 50 Day Moving Average of $3.91BiondVax Pharmaceuticals (NASDAQ:BVXV) Shares Pass Below 50 Day Moving Average of $3.91
americanbankingnews.com - April 17 at 2:06 AM
BiondVax Announces Exercise in Full of Underwriters Over-Allotment Option in Follow-on OfferingBiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering
finance.yahoo.com - February 10 at 8:22 PM
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary SharesBiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares
finance.yahoo.com - January 29 at 8:04 AM
BiondVax Announces Third Quarter 2020 Financial Results & Business UpdateBiondVax Announces Third Quarter 2020 Financial Results & Business Update
finance.yahoo.com - January 28 at 7:42 PM
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary SharesBiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares
finance.yahoo.com - January 28 at 7:42 PM
BiondVax Announces Appointment of Amir Reichman as New CEOBiondVax Announces Appointment of Amir Reichman as New CEO
finance.yahoo.com - January 21 at 7:23 AM
Why BiondVax Pharmaceuticals Stock Imploded TodayWhy BiondVax Pharmaceuticals Stock Imploded Today
finance.yahoo.com - October 31 at 9:05 AM
Biondvax Pharmas flu vaccine candidate unsuccessful in late-stage studyBiondvax Pharma's flu vaccine candidate unsuccessful in late-stage study
seekingalpha.com - October 23 at 1:56 PM
/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd.//C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./
finance.yahoo.com - October 23 at 1:56 PM
Biondvax Pharmaceuticals Ltd - ADRBiondvax Pharmaceuticals Ltd - ADR
reuters.com - September 2 at 9:39 AM
BiondVax Pharmaceuticals Ltd. (BVXV)BiondVax Pharmaceuticals Ltd. (BVXV)
ca.finance.yahoo.com - September 2 at 9:39 AM
BiondVax Pharmaceuticals: A Small, Undervalued Biotech CompanyBiondVax Pharmaceuticals: A Small, Undervalued Biotech Company
seekingalpha.com - September 1 at 6:54 PM
BVXV: Phase 3 Data for Universal Flu Vaccine in Late September to Late October 2020…BVXV: Phase 3 Data for Universal Flu Vaccine in Late September to Late October 2020…
finance.yahoo.com - August 31 at 12:45 PM
BiondVax Announces Second Quarter 2020 Financial ResultsBiondVax Announces Second Quarter 2020 Financial Results
finance.yahoo.com - August 20 at 5:58 PM
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial UpdateBiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
finance.yahoo.com - August 13 at 7:26 PM
Keep an eye on the momentum at Biondvax PharmaceuticalsKeep an eye on the momentum at Biondvax Pharmaceuticals
uk.finance.yahoo.com - July 24 at 8:23 AM
Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 ViewsMid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 Views
www.benzinga.com - July 14 at 12:08 PM
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergans Botox Gets Label Expansion, 3 IPOsThe Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
www.msn.com - July 10 at 9:08 AM
Botox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is HereBotox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is Here
www.nasdaq.com - July 10 at 9:08 AM
Could Biondvax Pharmaceuticals (NAQ:BVXV) be a turtle trade?Could Biondvax Pharmaceuticals (NAQ:BVXV) be a turtle trade?
uk.finance.yahoo.com - July 10 at 12:01 AM
Here is What Hedge Funds Think About Nautilus, Inc. (NLS)Here is What Hedge Funds Think About Nautilus, Inc. (NLS)
finance.yahoo.com - July 5 at 11:41 PM
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical TrialLast of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
finance.yahoo.com - July 1 at 8:22 AM
BiondVax Announces First Quarter 2020 Financial ResultsBiondVax Announces First Quarter 2020 Financial Results
finance.yahoo.com - June 30 at 5:55 PM
BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81…BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81…
finance.yahoo.com - June 16 at 5:55 PM
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateBiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
finance.yahoo.com - June 12 at 9:39 AM
BRIEF-BiondVaxs M-001 Universal Influenza Vaccine Candidate Achieves Primary Endpoints In Phase 2 TrialBRIEF-BiondVax's M-001 Universal Influenza Vaccine Candidate Achieves Primary Endpoints In Phase 2 Trial
www.reuters.com - June 10 at 8:24 PM
NIH Report on Phase 2 Clinical Trial of BiondVaxs M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints AchievedNIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
finance.yahoo.com - June 10 at 9:29 AM
BiondVax Announces Receipt of $4.2 Million Through Exercise of WarrantsBiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
finance.yahoo.com - May 20 at 8:20 AM
How BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Can Impact Your Portfolio VolatilityHow BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Can Impact Your Portfolio Volatility
finance.yahoo.com - May 9 at 12:19 PM
BiondVax Announces Upcoming Expiration of Public WarrantsBiondVax Announces Upcoming Expiration of Public Warrants
finance.yahoo.com - May 4 at 9:48 AM
As Biondvax Pharmaceuticals hits a yearly high, is it too late to buy shares?As Biondvax Pharmaceuticals hits a yearly high, is it too late to buy shares?
uk.finance.yahoo.com - May 1 at 7:07 AM
Biondvax Pharmaceuticals (NAQ:BVXV) price about to hit new 52-week highBiondvax Pharmaceuticals (NAQ:BVXV) price about to hit new 52-week high
uk.finance.yahoo.com - May 1 at 7:07 AM
Seasonal Influenza Vaccine Market 2019 Analysis and Precise Outlook - DaiichiSankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals LtdSeasonal Influenza Vaccine Market 2019 Analysis and Precise Outlook - DaiichiSankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd
www.marketwatch.com - April 30 at 4:02 PM
Influenza Vaccines Market Analysis and Precise Outlook - Sanofi Pasteur, GlaxoSmithKline(GSK), SeqirusInfluenza Vaccines Market Analysis and Precise Outlook - Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus
www.marketwatch.com - April 28 at 1:09 PM
Pipeline Review of the Influenza A Virus, H3N2 Subtype Infections - H1 2020 - ResearchAndMarkets.comPipeline Review of the Influenza A Virus, H3N2 Subtype Infections - H1 2020 - ResearchAndMarkets.com
www.businesswire.com - March 28 at 12:18 AM
Influenza Therapeutics Market provides an in-depth insight of Sales and Trends Forecast to 2026Influenza Therapeutics Market provides an in-depth insight of Sales and Trends Forecast to 2026
www.marketwatch.com - March 26 at 8:27 AM
New Directors Elected to BiondVax's Board of DirectorsNew Directors Elected to BiondVax's Board of Directors
finance.yahoo.com - March 24 at 5:52 PM
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical TrialBiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
finance.yahoo.com - March 19 at 9:09 AM
Influenza Vaccines Market : Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2025Influenza Vaccines Market : Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2025
www.marketwatch.com - March 4 at 7:27 AM
United States Influenza Vaccines Market Size Analysis By Growth, Emerging Trends and Future Opportunities Till 2025United States Influenza Vaccines Market Size Analysis By Growth, Emerging Trends and Future Opportunities Till 2025
www.marketwatch.com - March 4 at 7:27 AM
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical TrialsPreliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
finance.yahoo.com - February 5 at 2:21 PM
Seasonal Influenza Vaccine Market Analysis By Growth, Emerging Trends, Share and ForecastSeasonal Influenza Vaccine Market Analysis By Growth, Emerging Trends, Share and Forecast
www.marketwatch.com - January 18 at 12:10 PM
Influenza Vaccines Market Analysis By Major Key Players Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma and Sanofi PasteurInfluenza Vaccines Market Analysis By Major Key Players Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma and Sanofi Pasteur
www.marketwatch.com - January 18 at 12:10 PM
BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled…BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled…
finance.yahoo.com - December 4 at 1:58 PM
BiondVax Announces Third Quarter 2019 Financial Results and Business UpdateBiondVax Announces Third Quarter 2019 Financial Results and Business Update
finance.yahoo.com - November 26 at 9:20 AM
BiondVax Pharmaceuticals Ltd. American Depositary Shares (BVXV) Earnings Report DateBiondVax Pharmaceuticals Ltd. American Depositary Shares (BVXV) Earnings Report Date
www.nasdaq.com - November 25 at 11:59 PM
Enrollment and Randomization of 12,463 Participants Complete in BiondVaxs Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trialEnrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial
finance.yahoo.com - November 18 at 7:35 AM
Do Directors Own BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Shares?Do Directors Own BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Shares?
finance.yahoo.com - November 11 at 8:42 AM
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial ResultsBiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
finance.yahoo.com - August 28 at 8:42 AM
BVXV: Raises $20 Million; Phase 3 Trial Fully Funded…BVXV: Raises $20 Million; Phase 3 Trial Fully Funded…
finance.yahoo.com - August 1 at 12:30 PM
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.